Effect of naproxen co-administration on valproate disposition

Biopharmaceutics and Drug Disposition

Volumn 21, Issue 6, 2000, Pages 235-242

  Addison, R S ^a,b   Parker Scott, S L ^a   Hooper, W D ^a   Eadie, M J ^a   Dickinson, R G ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

oxidation; Drug interaction; Glucuronidation; Naproxen; Protein binding; Valproic acid

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DRUG METABOLITE; GLUCURONIDE; INZA; LAMOTRIGINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PANAPENEM; PENEM DERIVATIVE; PLASMA PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BINDING SITE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG URINE LEVEL; GLUCURONIDATION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NORMAL HUMAN; PLASMA CLEARANCE; VOLUNTEER;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; AREA UNDER CURVE; BIOTRANSFORMATION; DRUG INTERACTIONS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUCURONIDES; HUMANS; MALE; MIDDLE AGED; NAPROXEN; OXIDATION-REDUCTION; SPECTROPHOTOMETRY, ULTRAVIOLET; VALPROIC ACID;

EID: 0034447687     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.235     Document Type: Article

References (24)

1. Quantitative metabolic profiling of valproic acid in humans using automated gas chromatographic/mass spectrometric techniques
2. Quantitative determination of valproic acid and 14 metabolites in serum and urine by gas chromatography/mass spectrometry
3. Urinary metabolites of valproic acid in epileptic patients
4. Aspects of dose-dependent metabolism of valproic acid
5. Sodium valproate acutely inhibits lamotrigine metabolism
6. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus
7. The mechanism of carbamazepine-valproate interaction in humans
8. Panipenum, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats
9. Simultaneous quantitative determination of naproxen, metabolite 6-0-desmethylnaproxen and their five conjugates in plasma and urine samples by high performance liquid chromatography on dynamically modified silica
10. Isolation and identification of 6-desmethyl-naproxen sulfate as a new metabolite of naproxen in human plasma
11. Nonlinear plasma level response to high doses of naproxen
12. The determination of naproxen by spectrofluorometry and its binding to serum proteins
13. Stereoselective binding properties of naproxen glucuronide diastereomers to proteins
14. Effect of felbamate on the plasma protein binding of valproate
15. In vivo plasma protein binding interaction between valproic acid and naproxen
16. Displacement of valproic acid and carbamazepine from protein binding in normal and uremic sera by tolmetin, ibuprofen and naproxen: Precence of inhibitor in uremic serum that blocks valproic acid-naproxen interactions
17. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyl-transferase 1A3
18. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs
19. Urinary excretion of valproate and some metabolites in chronically treated patients
20. Effect of felbamate on valproic acid disposition in healthy volunteers: Inhibition of β-oxidation
21. Apparent autoinduction of valproate β-oxidation in humans
22. Variability in level dose ratio of valproate: Monotherapy versus polytherapy
23. Steady state dispositions of valproate and diflunisal alone and co-administered to healthy volunteers
24. Studies on the renal excretion of the acyl glucuronide, phenolic and sulphate conjugates of diflunisal